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Abstract. Background/Aim: The oxazaphosphorines,
ifosfamide and cyclophosphamide, represent a class of
alkylating agents. The aim of the present in vitro study was to
compare antileukemic activity of 4-hydroperoxyifosfamide (4-
OOH-IF) and 4-hydroperoxycyclophosphamide (4-OOH-CP).
Materials and Methods: The experiments were performed on
MOLT-4 and ML-1 cells. The research was conducted using
flow cytometry fluorescein diacetate/propidium iodide (PI),
fluorescein-conjugated annexin V/PI, CaspGLOW Red Active
Caspase-8 and -9, CellEvent™ Caspase-3/7 Green assays,
and tetramethylrhodamine ethyl ester test. Results: 4-OOH-IF
and 4-OOH-CP distinctly reduced cell viability and triggered
apoptosis and necrosis, causing changes in intracellular
esterase activity, plasma membrane structure and integrity,
caspase activation, and mitochondrial membrane potential.
The oxazaphosphorines were responsible for the different
antileukemic activities. 4-Hydroperoxyifosfamide appeared
to be less cytotoxic against the leukemia cells than 4-
hydroperoxycyclophosphamide. MOLT-4 cells were more
sensitive to the action of the oxazaphosphorines than ML-1
cells. Conclusion: The findings provide a new insight on the
mechanisms of cytotoxic action of 4-OOH-IF and 4-OOH-
CP on the human acute lymphoblastic and myeloblastic
leukemia cells.
Ifosfamide and cyclophosphamide represent the oxaza-
phosphorine drugs widely used in clinical practice for their
anticancer activity (1-3). Under in vivo conditions, both
ifosfamide and cyclophosphamide require metabolic
activation by specific hepatic cytochrome enzymes to become
therapeutically active (2-4). 4-Hydroperoxyifosfamide (4-
OOH-IF, D-18851, Figure 1) and 4-hydroperoxycyclo-
phosphamide (4-OOH-CP, D-18864, Figure 1) do not require
such metabolic activation in liver and can be applied under
in vitro conditions (2).
Cell viability and death are two very important parameters
that allow assessment of antileukemic activity of different
chemical compounds, e.g. potential anticancer agents (5, 6).
Cell viability is highly dependent on the processes of
regulated death which can be initiated by various
extracellular and intracellular stimuli (7, 8). Apoptosis and
necrosis are two distinct modalities of cell death (9, 10)
which can be triggered through the two main pathways,
namely the extrinsic/receptor, and intrinsic/mitochondrial
pathways (10, 11). Initiator caspase-8 and caspase-9 are
important mediators of apoptotic cell death which occurs
through the receptor and mitochondrial pathways,
respectively, and consequently by executive caspase-3/7
activation (12-15). It is accepted that mitochondria play an
essential role during apoptotic and necrotic cell death (16-
21). According to the recommendations of the Nomenclature
Committee on Cell Death, when investigating cytotoxic
agents, quantifiable biochemical parameters, such as plasma
membrane structure and integrity, activation of caspases, loss
of mitochondrial membrane potential, which accompany
regulated cell death induced by such agents, should be
determined (8, 10, 11).
The aim of the present study was to compare the in vitro
antileukemic activity of 4-hydroperoxyifosfamide and 
4-hydroperoxycyclophosphamide. The influence of these
oxazaphosphorines on cell viability, and apoptotic and
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necrotic death was evaluated. After application of these
agents, the intracellular esterase activity, plasma membrane
impairment, phosphatidylserine externalization, caspase-8, -
9, and -3/7 activity, and loss of mitochondrial membrane
potential were analyzed.
Materials and Methods
Chemicals. 4-Hydroperoxyifosfamide (D-18851, cis-(±)-3-(2-
chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2-oxide-2H-
1,3,2-oxazaphosphorine-4-yl-hydroperoxide; 4-OOH-IF) and 4-
hydroperoxycyclophosphamide (D-18864, cis-(±)-2-(bis(2-chloro-
ethyl)amino)tetrahydro-2-oxide-2H-1,3,2-oxazaphosphorine-4-yl-
hydroperoxide; 4-OOH-CP) (Figure 1) were synthesized at
NIOMECH - IIT GmbH (Bielefeld University, Bielefeld,
Germany). All solutions were freshly-prepared directly before
treatment of cells.
RPMI-1640 medium and fetal calf serum, and Hank’s balanced
salt solution (HBSS) were obtained from Gibco BRL Life
Technologies (Waltham, MA, USA). L-Glutamine, antibiotic
antimycotic solution (AAS), and propidium iodide (PI) were
purchased from Sigma Aldrich (St. Louis, MO, USA). Fluorescein
diacetate (FDA; Sigma Aldrich) and tetramethylrhodamine ethyl
ester perchlorate (TMRE; Sigma Aldrich), were kindly provided by
the Pavol Jozef Šafárik University in Košice (Košice, Slovakia).
Aqua pro injectione and 0.9% NaCl were obtained from Polpharma
S.A. (Starogard Gdański, Poland), phosphate-buffered saline (PBS)
from BioMed (Lublin, Poland), and Hemacolor staining set from
Merck KGaA (Darmstadt, Germany). CaspGLOW Red Active
Caspase-8 Staining Kit and CaspGLOW Red Active Caspase-9
Staining Kit were purchased from Biovision (Milpiats, CA, USA),
and CellEvent™ Caspase-3/7 Green Flow Cytometry Assay Kit
from Molecular Probes (Eugene, OR, USA). Annexin V-FITC
Apoptosis Detection Kit were obtained from Becton Dickinson
Pharmingen™ (San Diego, CA, USA). 
Leukemia cells. Human acute lymphoblastic leukemia MOLT-4 cells
and human acute myeloblastic leukemia ML-1 cells were obtained
from the European Collection of Cell Cultures (Salisbury, Wiltshire,
UK). MOLT-4 and ML-1 cells were cultured in RPMI-1640 medium
supplemented with 10% fetal calf serum, 2 mM L-glutamine, and
AAS containing 20 units of penicillin, 20 μg streptomycin and 50
ng amphotericin B. The leukemia cells were passaged every third
day. MOLT-4 and ML-1 cells were grown at 37˚C in an atmosphere
of 5% CO2 in air (HERAcell incubator; KendroLab, Warsaw,
Poland). The human acute leukemia cells were seeded in 24-well
plates at a density of 15×104 before performing each experiment.
Leukemia cell treatment with oxazaphosphorines. After dilution of
the cell suspension to a density of 15×104 cells/ml in complete
RPMI-1640 medium, MOLT-4 and ML-1 cells were treated with 4-
OOH-IF and 4-OOH-CP. MOLT-4 cells were exposed to the action
of 4-OOH-IF and 4-OOH-CP at the doses of 0.5 μg/ml, 1 μg/ml,
and 2.5 μg/ml medium, and ML-1 cells were treated with these
agents at the doses of 1 μg/ml, 5 μg/ml, and 10 μg/ml medium. The
doses of oxazaphosphorines used in the present studies were based
on the unpublished data. 4-OOH-IF and 4-OOH-CP were dissolved
in aqua pro injectione directly before application. The control
consisted of untreated MOLT-4 and ML-1 cells. 
Analyses of human leukemia cells exposed to 4-OOH-IF and 4-
OOH-CP. The changes occurring in MOLT-4 and ML-1 cells after
application of 4-OOH-IF and 4-OOH-CP, were determined using
flow cytometry FDA/PI, annexin V-FITC/PI, CaspGLOW Red
Active Caspase-8 and -9, CellEvent™ Caspase-3/7 Green, and
TMRE assays. 
Flow cytometric FDA/PI assay. Using the FDA/PI assay, FDA is
taken up by live cells and hydrolyzed by intracellular esterases,
and PI is excluded by an intact cell membrane. Briefly, the
leukemia cell suspension containing 5×105 cells was centrifuged
for 7 min at 100 × g and 37˚C (MPW-351RH centrifuge; Med.
Instruments, Warszawa, Poland), and the cell pellet was
resuspended in 1 ml of warm HBSS. Then, 10 μl of FDA working
solution, at a concentration of 1 μg/ml in HBSS, was added and
the leukemia cells were incubated in the dark for 15 min at 37˚C.
After the incubation with FDA, 20 μl of PI working solution, at a
concentration of 30 μg/ml in 0.9% NaCl, was added, and the cells
were incubated for additional 5 min. Incubation of cells in the
presence of both FDA and PI labeled live cells as green, and cells
with impaired plasma membrane integrity as red. Cell samples
were placed on ice, away from light, and FDA and PI was
immediately measured using flow cytometry (Becton Dickinson,
San Jose, CA, USA).
Flow cytometric annexin V-FITC/PI assay. Using Annexin V-
FITC Apoptosis Detection Kit, the procedure of dual staining of
cells was performed. Briefly, leukemia cell suspension containing
5×105 cells was washed twice with cold PBS, the cells were
centrifuged for 7 min at 100 × g and 4˚C (MPW-351RH
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Figure 1. Chemical structures of 4-hydroperoxyifosfamide (D-18851, 
4-OOH-IF) and 4-hydroperoxycyclophosphamide (D-18864, 4-OOH-CP).
centrifuge; Med. Instruments), and resuspended in 100 μl of cold
binding buffer. Then 2.5 μl of annexin V-FITC and 2.5 μl of PI
staining solution were added and the cells were incubated in the
dark for 15 min at room temperature. Following the incubation,
400 μl of binding buffer was added to each tube. Cell samples
were placed on ice, away from light, and FITC and PI
fluorescence was immediately measured using flow cytometry
(Becton Dickinson). 
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Figure 2. Effects of 4-hydroperoxyifosfamide (4-OOH-IF) and 4-hydroperoxycyclophosphamide (4-OOH-CP) on the viability of MOLT-4 and ML-1
cells determined by flow cytometric fluorescein diacetate (FDA)/propidium iodide (PI) assay. Representative dot plots for MOLT-4 (A) and ML-1
(B) cells stained with FDA (FL1-H) and PI (FL3-H) observed 48 h after application of oxazaphosphorines. Three leukemia cell populations were
distinguished: (I) FDA+/PI−, (II) FDA−/PI−, and (III) FDA−/PI+. The percentage values of the different cell populations of MOLT-4 (C) and
ML-1 (D) cells were determined 24 h and 48 h after application of 4-OOH-IF and 4-OOH-CP. The obtained data are presented as mean values±SD,
calculated from three independent experiments carried out in triplicate. Values not significantly different at p<0.05 according to Tukey’s multiple
range test: #compared to controls; ^between the same agent at different doses; *between agents at the same dose; +between time points.
Flow cytometric caspase-8 and -9 assays. Cells were analyzed using
CaspGLOW Red Active Caspase-8 Staining Kit and CaspGLOW
Red Active Caspase-9 Staining Kit. The fluorescent markers,
caspase-8 inhibitor IETD-fluoromethylketone conjugated to sulfo-
rhodamine (Red-IETD-FMK), and caspase-9 inhibitor LEHD-
fluoromethylketone conjugated to sulfo-rhodamine (Red-LEHD-
FMK), irreversibly bind, respectively, to caspase-8 and caspase-9
activated in apoptotic cells. Briefly, the cell suspension was
centrifuged for 7 min at 100 × g and 37˚C (MPW-351RH; Med.
Instruments), and the supernatant was removed by aspiration. The
cell pellet was resuspended in 150 μl of PBS, and 0.5 μl of Red-
IETD-FMK or 0.5 μl of Red-LEHD-FMK was added into each
sample, and the cells were incubated for 1 h at 37˚C. Then the cell
suspension was centrifuged, the supernatant was removed, and the
cells were washed twice in 500 μl of wash buffer. After the washing
step, the cells were resuspended in 300 μl of wash buffer, put on ice
and analyzed using flow cytometry (Becton Dickinson). 
Flow cytometry caspase-3/7 assay. Cells were analyzed using
CellEvent™ Caspase-3/7 Green Flow Cytometry Assay Kit.
CellEvent™ Caspase-3/7 Green Detection Reagent, a fluorogenic
substrate for activated caspases-3 and -7, consisting of a four-amino
acid peptide (DEVD) is conjugated to a nucleic acid-binding dye.
After activation of caspase-3/7 in apoptotic cells, DEVD peptide is
cleaved, enabling the dye to bind to DNA and producing a bright,
fluorogenic response. Briefly, the cell suspension was centrifuged
for 7 min at 100 × g and 37˚C (MPW 351 RH; Med. Instruments)
and the supernatant was removed by aspiration. The cell pellet was
resuspended in 500 μl of PBS. Then 0.5 μl of CellEvent™ Caspase-
3/7 Green Detection Reagent was added to each sample and the
cells were incubated for 30 min at 37˚C. After incubation, the
leukemia cell samples were analyzed by flow cytometry (Becton
Dickinson). 
Flow cytometric analysis of mitochondrial membrane potential
(MMP). The MMP was analyzed by means of the lipophilic
cationic dye TMRE. Retention of TMRE, cell-permeable,
positively-charged, red-orange dye, depends on MMP – more
greatly polarized mitochondria accumulate more cationic dye,
while depolarized mitochondria accumulate less dye. A TMRE
stock solution was prepared at a concentration of 10 mM in
dimethyl sulfoxide and stored at −20˚C. The final concentration of
TMRE staining solution used was 100 nM. Briefly, the leukemia
cell suspension containing 2.5-5×105 cells/ml was centrifuged for
7 min at 100 × g and 37˚C (MPW-351RH; Med. Instruments). The
cell pellet was then washed twice in 1 ml of warm HBSS,
resuspended in 100 μl of 100 nM TMRE, and incubated at 37˚C in
the darkness. After 20-min incubation, the cells were washed with
1 ml of warm HBSS and centrifuged. Next, the supernatant was
discarded and the cells were resuspended in 500 μl of HBSS.
TMRE fluorescence was immediately detected by flow cytometry
(Becton Dickinson). 
Statistical evaluation. All flow cytometric data were analyzed using
Flowing Software version 2.5.1 (Perttu Terho, Turku Centre of
Biotechnology, University of Turku, Finland). The statistical
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Figure 3. Effects of 4-hydroperoxyifosfamide (4-OOH-IF) and 4-hydroperoxycyclophosphamide (4-OOH-CP) on apoptotic and necrotic death of
MOLT-4 and ML-1 cells determined by flow cytometric annexin V-fluorescein isothiocyanate (FITC)/propidium iodide (PI) assay. Representative
dot plots for MOLT-4 (A) and ML-1 (B) cells obtained 48 h after application of the oxazaphosphorines; FL1-H: green fluorescence of FITC,
FL2-H: red fluorescence of PI. Based on the plasma membrane diversity and impairment, the populations of live cells (I, annexin V-FITC−/PI−),
early apoptotic cells (II, annexin V-FITC+/PI−), and late apoptotic and necrotic cells (III, annexin V-FITC+/PI+) were distinguished. The percentage
of annexin V-FITC+/PI− and annexin V-FITC+/PI+ MOLT-4 (C) and ML-1 (D) cells was determined 48 h after application of the tested
oxazaphosphorine agents. The data are presented as the mean±SD calculated from three independent experiments carried out in duplicate. Values
not significantly different at p<0.05 according to the Tukey’s multiple range test: #compared to controls; ^between the same agent at different doses.
significance for the data was evaluated by STATISTICA 10
(StatSoft, Krakow, Poland) using one-way analysis of variance
followed by Tukey’s honestly significant differences multiple range
test. A difference with p<0.05 was considered statistically
significant. 
Results
The influence of two oxazaphosphorine agents, 4-OOH-IF
and 4-OOH-CP, on alterations in the frequency of three
leukemia cell populations FDA+/PI−, FDA−/PI−, and
FDA−/PI+ (Figure 2), the percentage values of both annexin
V-FITC+/PI− cells and annexin V-FITC+/PI+ cells (Figure 3),
as well as in the frequency of cells with active caspase-8, -9,
and -3/7 (Figure 4) and cells with dissipated MMP (Figure 5)
were determined. The cytotoxic activity of the
oxazaphosphorines depended on the agent tested, its dose,
and the leukemia cell line used (Figures 2-5). 4-OOH-CP
reduced leukemia cell viability (Figure 2), triggered apoptotic
and necrotic cell death (Figure 3), promoted caspase activity
(Figure 4), and caused the loss of MMP (Figure 5) to a higher
degree than did 4-OOH-IF. The oxazaphosphorine agents led
to weaker cytotoxic effects in ML-1 cells than in MOLT-4
cells (Figure 2-5).
Discussion
In the present study, the in vitro cytotoxic activity of 4-OOH-
IF and 4-OOH-CP against human acute lymphoblastic
leukemia MOLT-4 cells and human acute myeloblastic
leukemia ML-1 cells was compared. After application of the
oxazaphosphorines, various patterns of changes in
intracellular esterase activity, plasma membrane integrity and
cell surface exposure of phosphatidylserine, caspase-8, -9,
and -3/7 activation, and the MMP were found in MOLT-4
and ML-1 cells. In general, 4-OOH-IF appeared to be less
cytotoxic than 4-OOH-CP against the human acute leukemia
cells, and MOLT cells were more sensitive than ML-1 cells
to the action of both oxazaphosphorine agents. 
The mechanisms of action of 4-OOH-IF and 4-OOH-CP
depend on their chemical structure and metabolism. The
oxazaphosphorine structure is composed of an
oxazaphosphorin-2-amine 2-oxide heterocycle containing
one atom of phosphorus, one atom of nitrogen and one of
oxygen. Ifosfamide and cyclophosphamide have an isomeric
structure with one or two 2-chloroethyl groups linked to the
nitrogen, respectively (2, 3). In aqueous solution, 4-OOH-
IF and 4-OOH-CP spontaneously and rapidly generate 4-
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Figure 4. Flow cytometric analysis of MOLT-4 and ML-1 cells with active caspase-8, -9, and -3/7, conducted 24 h after application of 
4-hydroperoxyifosfamide (4-OOH-IF) and 4-hydroperoxycyclophosphamide (4-OOH-CP). Representative histograms of MOLT-4 (A) and ML-1 (B)
cells obtained after their exposure to the action of 4-OOH-IF and 4-OOH-CP; H-2: cells with active caspase-3/7; FL1-H: CellEvent™ Caspase-
3/7 Green fluorescence. The percentage of MOLT-4 (C) and ML-1 (D) cells with active caspase-8, -9, and -3/7 was determined 24 h after their
exposure to the action of 4-OOH-IF and 4-OOH-CP. The data are presented was the mean±SD calculated from three independent experiments
carried out in duplicate. All data differed significantly at p<0.05 according to Tukey’s multiple range test.
hydroxyifosfamide (4-OH-IF) and 4-hydroxycyclo-
phosphamide (4-OH-CP), respectively, moreover both
agents additionally generate HO-radicals and hydrogen
peroxide. 4-OH-IF degrades via aldoifosfamide to
ifosfamide mustard and acrolein, while 4-OH-CP degrades
via aldophosphamide to phosphoramide mustard and
acrolein. It is accepted that ifosfamide mustard and
phosphoramide mustard are the major reactive alkylating
agents of 4-OOH-IF and 4-OOH-CP. The cytotoxic effects
of these mustard agents result from intermolecular,
alkylation or bisalkylation reactions relating to the
intermediate electrophilic aziridinyl species. The reactive
alkylating compounds are involved in cytotoxic reactions
because they can bind to a variety of cellular molecules
disturbing normal processes occurring in the cell (1-3).
The present findings indicate that the action of 4-OOH-
IF and 4-OOH-CP resulted in induction of apoptosis and
necrosis. In human acute leukemia cells undergoing
regulated death, 4-OOH-IF and 4-OOH-CP caused plasma
membrane impairment and loss of its phospholipid
asymmetry by phosphatidylserine externalization, as well as
mitochondrial dysfunction. Moreover, these oxaza-
phosphorines triggered caspase-dependent apoptosis through
the receptor and mitochondrial pathways by caspase-8, -9,
and -3/7 cascade activation. These are the first data
comparing the regulated cell death-inducing potential of 4-
OOH-IF and 4-OOH-CP in human acute lymphoblastic and
myeloblastic leukemia cells. 
Conclusion 
To summarize, the varied responses of MOLT-4 and 
ML-1 cells to the action of 4-OOH-IF and 4-OOH-CP
depend on the chemical structure of the agent and the cell
line status. The different in vitro antileukemic activities
of these oxazaphosphorine agents are associated with their
potential for triggering regulated cell death, which is
accepted to be one of the mechanisms of cancer therapy.
Understanding the processes of regulated cell death
induced by oxazaphosphorines is of key importance in
chemotherapy.
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Figure 5. Effects of 4-hydroperoxyifosfamide (4-OOH-IF) and 4-hydroperoxycyclophosphamide (4-OOH-CP) on changes in mitochondrial membrane
potential (MMP) of MOLT-4 and ML-1 cells. Representative dot plots for MOLT-4 (A) and ML-1 (B) cells obtained 48 h after their exposure to the
action of the two oxazaphosphorines using flow cytometric test; I: cells with high MMP, II: cells with low MMP. The percentage of MOLT-4 (C)
and ML-1 (D) cells with low MMP observed 24 h and 48 h after application of the tested oxazaphosphorine agents. The data are presented as the
mean±SD calculated from three independent experiments carried out in triplicate. Values not significantly different at p<0.05 according to the
Tukey’s multiple range test: #compared to controls; ^between the same agent at different doses; *between different agents at the same dose.
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